Form 4: Corcept Therapeutics Executive William Guyer Reports Stock Option Exercise and Sale
SEC Form 4
William Guyer, Chief Development Officer of Corcept Therapeutics, executed a stock option exercise and sale on May 6, 2025, according to a Form 4 filing.
Summary
- On May 6, 2025, William Guyer, Chief Development Officer of Corcept Therapeutics, exercised stock options to acquire 7,060 shares of common stock at a price of $21.65 per share.
- Simultaneously, Guyer sold 7,060 shares of common stock at a price of $74.3134 per share.
- These transactions were executed under a pre-arranged 10b5-1 trading plan adopted on November 27, 2024.
- Following these transactions, Guyer directly owns 5,487 shares of Corcept Therapeutics common stock and holds options for 442,262 shares.
Sentiment
Score: 5
Explanation: The Form 4 filing is a neutral disclosure of insider trading activity. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Future Outlook
The filing does not contain any specific forward-looking statements regarding the company's future performance or prospects.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.
Comparison to Industry Standards
- Executive stock option exercises and sales are common in publicly traded companies, particularly in the pharmaceutical and biotechnology sectors.
- The use of 10b5-1 plans is a standard practice to allow insiders to trade company stock without concerns about insider trading violations.
- Comparing the exercise price and sale price with industry peers can provide insights into the relative attractiveness of Corcept's stock options.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership of shares.
- The filing provides transparency to stakeholders regarding insider trading activities.
Key Dates
| Date | Description |
|---|---|
| 2024-11-27 | Date of adoption of the 10b5-1 trading plan by William Guyer. |
| 2025-05-06 | Date of stock option exercise and sale by William Guyer. |
| 2025-05-08 | Date of signature of the Form 4 filing. |
| 2031-09-01 | Expiration date of the stock options. |
Keywords
Form 4, Corcept Therapeutics, CORT, William Guyer, Stock Options, 10b5-1 Plan, Executive Compensation, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.